论文部分内容阅读
尼曼-皮克C1型类似蛋白(NPC1L)1在依折麦布降脂治疗中起到举足轻重的作用。同时依折麦布可以降低血清二肽基肽酶(DPP)-4活性和增加血清活性胰高血糖素样肽(GLP)-1水平,在糖尿病患者中对血糖可以进行一定程度的控制。临床研究表明,依折麦布具有降脂,预防冠心病,降低心血管发病率,尤其是应用在冠心病并发糖尿病患者中。近年来人们对NPC1L1、DPP-4和GLP-1在冠心病并发糖尿病患者中的作用有了更深一步的研究。
Niemann-Pick C1-like protein (NPC1L) 1 plays a pivotal role in the ezetimibe lipid-lowering therapy. At the same time, ezetimibe may lower serum dipeptidyl peptidase (DPP) -4 activity and increase serum active glucagon-like peptide (GLP) -1 levels, with some degree of control of blood glucose in diabetic patients. Clinical studies have shown that ezetimibe with lipid-lowering, prevention of coronary heart disease, reduce cardiovascular morbidity, especially in patients with coronary heart disease complicated by diabetes. In recent years, people have a deeper study of the role of NPC1L1, DPP-4 and GLP-1 in patients with coronary heart disease complicated with diabetes.